Entrada Therapeutics, Inc.
TRDA· Nasdaq
Released Feb 27, 2025, before the open
10-K filed Feb 27, 2025, 58 days after period end · 0001689375-25-000011
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $37.40M | $41.85M | — | — |
| Net Income | $1.13M |
Entrada Therapeutics, Inc. · CIK 1689375 · Engraved from SEC EDGAR
| -$9.54M |
| -$24.63M |
| -$18.45M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.